Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07419321 · ClinicalTrials.gov registry record

Social Isolation and Aging in Schizophrenia

A clinical trial of Schizophrenia and Related Disorders, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
650
Enrollment target
4
Study locations

NCT07419321: Recruiting study of Schizophrenia and Related Disorders, sponsored by Icahn School of Medicine at Mount Sinai.

NCT07419321 is a study of Schizophrenia and Related Disorders that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 650 participants, above the 119-participant average among 4 other Schizophrenia and Related Disorders trials with a reported enrollment target (446% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07419321, a study of Schizophrenia and Related Disorders, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
650 participants
Enrollment target
4
Study locations

Study Summary

Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors. Remarkably, the direct adverse health effects of key clinical characteristics of SZ have rarely been considered. In the general population, the absence of social contact is known to pose enormous challenges for physical health, especially at older ages. Given that social isolation is a persistent and disabling feature of SZ, it is possible that this behavior may contribute to the premature manifestation of health conditions in SZ. Building on rich pilot data pointing to significant associations between social isolation and long-term perceived health in SZ, the overarching goal is to test whether and how social isolation contributes to the health challenges of individuals with SZ as they age. With participants from Europe (EU-GEI) and the US (Olin Neuropsychiatry Research Center), the researchers will create a longitudinal database of 650 participants, including 500 individuals with SZ, and 150 of their unaffected siblings. The researchers will apply an accelerated longitudinal design by reassessing and by examining medical records of research participants who were first evaluated between the ages of 20-55 and are now 40-70 years of age, a period when many medical conditions and health problems tend to manifest. The researchers will determine the age-related association between social isolation and adverse health outcomes in SZ, test for familiality, directionality, and factors moderating

Primary Outcome

Physician diagnosed medical conditions - Medical records from hospitals and general practitioners will be reviewed to identify the occurrence and timing of any newly diagnosed conditions (e.g., cardiovascular disease, COPD, diabetes).

Study Locations (4)

Other

  • Hospital General Universitario Gregorio Marañon - Madrid
  • King's College London - London

Connecticut

  • Olin Neuropsychiatry Research Center, Hartfort - Hartford

North Holland

  • AUMC, University Hospital - Amsterdam

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2024-01-09
Est. Completion 2027-07

What NCT07419321 shows while recruiting

NCT07419321 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 4 other Schizophrenia and Related Disorders trials with a reported enrollment target (446% higher).

The record links to 1 condition, with Schizophrenia and Related Disorders appearing as the primary indexed condition, and to 0 interventions.

NCT07419321 reports a single indexed study location in Other, Connecticut, North Holland.

Frequently Asked Questions

What is clinical trial NCT07419321 about?

NCT07419321 is a clinical study titled "Social Isolation and Aging in Schizophrenia". Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical...

What is the current status of trial NCT07419321?

This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2024-01-09. Estimated completion is 2027-07.

What conditions does trial NCT07419321 study?

This clinical trial studies the following conditions: Schizophrenia and Related Disorders.

Who is sponsoring clinical trial NCT07419321?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07419321 being conducted?

This trial has 4 study locations across Connecticut, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia and Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02934477 · 650 participants

    Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

  • NCT04579120 · 650 participants

    Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

  • NCT04875702 · 650 participants · Phase 4

    Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

  • NCT05046600 · 650 participants

    Registry of Arthrex Hand and Wrist Products

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07419321, the US trial registry maintained by the National Library of Medicine. NCT07419321 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.